BioWorld - Articles

Follow-on offerings of biopharma companies in January 2020

Jan. 31, 2020

Follow-ons completed by biopharma companies, including: Adaptimmune, Albireo, Alector, Apellis, Applied, Aptinyx, Autolus, Biohaven, Blueprint Medicines, Catabasis, Concert, DBV, Denali, Heat Biologics, Hutchison China Meditech, Immunogen, Intelgenx, Intra-Cellular, Matinas, Mirati, Mirum, Nanoviricides, Osmotica, Trillium, Xenon, Zai Lab, Zymeworks.

Other financings of public biotechnology companies in January 2020

Jan. 31, 2020

Private placements and other private financings of public biopharma companies, including: Advaxis, Algernon, Alimera, Armata, Azurrx, Bergenbio, Biocurepharm Korea, Bonus Biogroup, Cellect, Chemocentryx, Cidara, Clovis, Cocrystal, Edesa, Epizyme, Eyegate, Genprex, Helix, Hemogenyx, Hemostemix, Infinity, Iterum, Kamada, Leap, Lineage Cell, Novus, Noxxon, Promis, Puretech, Saniona, Sellas, Seneca, Spero, Tetra, Tetraphase, Titan, Vaxil, Vitro, Wize.

Venture capital and other private biopharma financings in January 2020

Jan. 31, 2020

Venture capital and other private financings of private biopharma companies, including: Adagene, Aegle, Agilvax, Airway, Alderaan, Aligos, Arpeggio, Biograil, Biointervene, Bionetix, Calidi, Cerebral, Codagenix, Domain, Empirico, Eqrx, Fusion, Genesen, Heparegenix, Idbydna, Immuneering, Jasper, Kyverna, Lyra, Nference, Northsea, Seekyo, Tarsus, Treadwell, Tscan, Tyra, Urania, Vectivbio.

Milestone payments from corporate partners in January 2020

Jan. 31, 2020

Triggered milestone payments disclosed by biopharma companies, including: BMS, Evotec, Gilead, Newsoara, Roche, Scholar Rock, Seattle Genetics, Zenith Epigenetics.

BioWorld and Nasdaq stock indices

Jan. 31, 2020

These graphs compare the performance of the biotech stocks for all of 2019 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.

Biggest gainers and losers for the week of Jan. 27-31, 2020

Jan. 31, 2020

The top 10 biopharma stock gainers and losers for the week, including: Acceleron, Amgen, Beigene, Biontech, Cortexyme, Precision, Reata, Syndax, United, Vir.

‘Wake-up call’

Current R&D investments insufficient to stem rising AMR tide

Jan. 28, 2020

By Peter Winter

Adding further evidence about the global threat of the increase of antimicrobial-resistant (AMR) infections and dearth of new antibiotics to treat those conditions, Thomas Cueni, chair of the AMR Industry Alliance, said the findings from the alliance’s newly released report are “a wake-up call” as they estimate current investments in AMR-relevant R&D are not enough to sustain a viable pipeline that will be needed to combat infectious diseases globally.

Gene therapies could add $45B to health care costs over next five years

Jan. 27, 2020

By Brian Orelli

New gene therapy treatments could add $45 billion to the cost of health care over the next five years, according to a new report from CVS Health Corp., of Woonsocket, R.I. While the number is staggering, without knowing the price of the currently unapproved therapies, how many patients will seek treatment and the likelihood of approval, the pharmacy benefit manager's estimate is basically an educated guess.